Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

On March 21, 2014, two new antibiotics with activity against methicillin-resistant Staphylococcus aureus (MRSA) each received unanimous recommendations from FDA Advisory Committees for approval for treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms.

FDA Advisory Committee Recommends Approval of Tedizolid and Dalbavancin